Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | protein kinase domain containing protein | 0.0052 | 0 | 0.5 |
Toxoplasma gondii | oxidoreductase, 2OG-Fe(II) oxygenase family protein | 0.0089 | 1 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0089 | 1 | 1 |
Toxoplasma gondii | oxidoreductase, 2OG-Fe(II) oxygenase family protein | 0.0089 | 1 | 1 |
Entamoeba histolytica | protein kinase domain containing protein | 0.0052 | 0 | 0.5 |
Trypanosoma brucei | 2OG-Fe(II) oxygenase superfamily, putative | 0.0089 | 1 | 1 |
Toxoplasma gondii | hypoxia- inducible factor prolyl hydroxylase (phd2), putative | 0.0089 | 1 | 1 |
Giardia lamblia | Kinase, CMGC GSK | 0.0052 | 0 | 0.5 |
Toxoplasma gondii | tetratricopeptide repeat-containing protein | 0.0089 | 1 | 1 |
Schistosoma mansoni | prolyl 4-hydroxylase alpha subunit 1 | 0.0089 | 1 | 1 |
Onchocerca volvulus | 0.0089 | 1 | 1 | |
Trichomonas vaginalis | CMGC family protein kinase | 0.0052 | 0 | 0.5 |
Giardia lamblia | Kinase, CMGC GSK | 0.0052 | 0 | 0.5 |
Leishmania major | hypothetical protein, unknown function | 0.0089 | 1 | 1 |
Plasmodium vivax | glycogen synthase kinase 3, putative | 0.0052 | 0 | 0.5 |
Entamoeba histolytica | protein kinase, putative | 0.0052 | 0 | 0.5 |
Plasmodium falciparum | glycogen synthase kinase 3 | 0.0052 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 1 | 1 |
Echinococcus multilocularis | prolyl 4 hydroxylase subunit alpha 1 | 0.0089 | 1 | 1 |
Trypanosoma cruzi | 2OG-Fe(II) oxygenase superfamily, putative | 0.0089 | 1 | 1 |
Echinococcus granulosus | prolyl 4 hydroxylase subunit alpha 1 | 0.0089 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0052 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0089 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0089 | 1 | 1 |
Loa Loa (eye worm) | prolyl 4-hydroxylase 2 | 0.0089 | 1 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.